Sunday, March 20, 2016

News: Medtech Announces First Sale of ROSA Spine in the United States to Miami Valley Hospital

MONTPELLIER, France, March 09, 2016 (GLOBE NEWSWIRE) -- MEDTECH (Euronext, FR0010892950 – ROSA), a company specialized in designing, developing and marketing innovative surgical assistance robots, today announced the first sale of its ROSA™ Spine robotic surgery system in the U.S. - to Miami Valley Hospital.

Image result for Miami Valley HospitalMiami Valley Hospital is a 970-bed medical facility in Dayton, Ohio. It is a recipient of the Healthgrades® “America’s 100 Best Hospitals’ Award™ in 2016 and has received the Healthgrades Distinguished Hospital Award – Clinical Excellence™ for three consecutive years from 2014 to 2016.

“Our hospital previously purchased two ROSA™ Brain systems in 2015 for our Neuroscience Institute and for training in our Brethen Center for Surgical Advancement in Robotics and Minimally Invasive Surgery,”said Mark Shaker, president and CEO of Miami Valley Hospital. “We are thrilled to be the first facility in the U.S. to now have ROSA™ Spine, and we are confident that Medtech’s robotic technology will expand our minimally invasive spinal surgery options for the region.”

ROSA™ Spine was granted FDA clearance in the U.S. in January 2016, and received the CE Mark in 2014. Medtech’s ROSA™ Brain received FDA approval in 2012 and is currently in use in 29 U.S. facilities.

“We are proud to officially have ROSA™ Spine in the U.S.,” said Bertin Nahum, CEO and founder of Medtech. “This technology allows surgeons to perform minimally invasive surgical procedures on the spine and increases the safety and reliability of these operations. The U.S. market is the world’s leading market for spine surgery, and this is a first step in bringing the benefits of ROSA™ Spine to an even greater number of patients.”

Founded in 2002 by Bertin NAHUM and based in Montpellier, MEDTECH is a European specialist in the design, development and marketing of innovative robotic appliances to assist surgeons during their medico-surgical interventions, thus contributing to the implementation of safer, more efficient, less-invasive treatment.

In 2007, MEDTECH developed ROSA™,  an innovative technological device devoted to  brain surgery procedures.  ROSA™ has been approved in Europe,  the United States and Canada.
In 2013 MEDTECH received the “European Company of the Year Award” in the “robotic neurosurgery” category from Frost & Sullivan.

In July 2014, MEDTECH obtained the CE marking for its new product ROSA™ Spine, a robotic- assistive device for minimally invasive surgery of the spine.

In October 2014, MEDTECH won the “Révélation” prize in the Mediterranean Deloitte Technology Fast 50 Awards.

In 2015 MEDTECH received the “2016 Company of the Year Award” in the “robotic neurosurgery” category from Frost & Sullivan.

In November 2015, MEDTECH was honored by Deloitte In Extenso for its excellent performance in the Technology Fast 50 Mediterranean Awards, in the “listed company” category.

In January 2016, MEDTECH obtained the FDA clearance for its new product, ROSA™ Spine, a robotic-assistive device for minimally invasive surgery of the spine.
Christophe Sibillin
Chief Financial Officer
Tel : +33 (0)4 67 10 77 40
Tel : +33 (0)1 53 67 36 77
Corinne Puissant
Alexandra Prisa (EU)
Tel. : +33(0)1 53 67 36 90
Joanna Zimmerman (US)
Tel : +1 646-536-7006

Published at Nasdaq GloneNewswire

No comments:

Post a Comment